Literature DB >> 17041228

Novel envelope determinants for CCR3 use by human immunodeficiency virus.

Marlén M I Aasa-Chapman1, Craig R Seymour, Ian Williams, Aine McKnight.   

Abstract

Human immunodeficiency virus type 1 can generally use CCR3 and CCR5 for cell entry. We show that envelopes with novel phenotypes arise during "coreceptor switch": one loses the ability to use CCR3 (R5-only phenotype), and another gains use of CXCR4 in addition to CCR5 and CCR3 (R3/R5/X4-using phenotype). The envelope determinants for CCR3 use mapped to three amino acids. One, N356 in conserved region 3, is a potential glycosylation site and has not previously been associated with coreceptor use. The other two, R440 and N448 in conserved region 4, are proximal to but distinct from residues already identified as being important for CCR5 binding.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17041228      PMCID： PMC1641764          DOI： 10.1128/JVI.01030-06

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  14 in total

1.  Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120.

Authors:  C Rizzuto; J Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

2.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

4.  Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants.

Authors:  A Carrillo; L Ratner
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

5.  Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles.

Authors:  R Shankarappa; P Gupta; G H Learn; A G Rodrigo; C R Rinaldo; M C Gorry; J I Mullins; P L Nara; G D Ehrlich
Journal:  Virology       Date:  1998-02-15       Impact factor: 3.616

6.  Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity.

Authors:  Jacqueline D Reeves; John L Miamidian; Mark J Biscone; Fang-Hua Lee; Navid Ahmad; Theodore C Pierson; Robert W Doms
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Development of the antibody response in acute HIV-1 infection.

Authors:  Marlén M I Aasa-Chapman; Anna Hayman; Philippa Newton; David Cornforth; Ian Williams; Persephone Borrow; Peter Balfe; Aine McKnight
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

8.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.

Authors:  George Lin; Graham Simmons; Stefan Pöhlmann; Frédéric Baribaud; Houping Ni; George J Leslie; Beth S Haggarty; Paul Bates; Drew Weissman; James A Hoxie; Robert W Doms
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species.

Authors:  Marlén M I Aasa-Chapman; Keith Aubin; Ian Williams; Aine McKnight
Journal:  Virology       Date:  2006-05-19       Impact factor: 3.616
View more
  12 in total

1.  In silico design of multi-target inhibitors for C-C chemokine receptors using substructural descriptors.

Authors:  Alejandro Speck-Planche; Valeria V Kleandrova
Journal:  Mol Divers       Date:  2011-10-22       Impact factor: 2.943

2.  In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies.

Authors:  Marlén M I Aasa-Chapman; Kelly M Cheney; Stéphane Hué; Anna Forsman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Áine McKnight
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

3.  Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates.

Authors:  Ashika Singh; Taryn Page; Penny L Moore; Rachel L Allgaier; Keshni Hiramen; Hoosen M Coovadia; Bruce D Walker; Lynn Morris; Thumbi Ndung'u
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

4.  Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype.

Authors:  R Nedellec; M Coetzer; N Shimizu; H Hoshino; V R Polonis; L Morris; U E A Mårtensson; J Binley; J Overbaugh; D E Mosier
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

5.  Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

Authors:  Thushan I de Silva; Marlén Aasa-Chapman; Matthew Cotten; Stéphane Hué; James Robinson; Frederic Bibollet-Ruche; Ramu Sarge-Njie; Neil Berry; Assan Jaye; Peter Aaby; Hilton Whittle; Sarah Rowland-Jones; Robin Weiss
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 6.  The puzzling role of CXCR4 in human immunodeficiency virus infection.

Authors:  Elisa Vicenzi; Pietro Liò; Guido Poli
Journal:  Theranostics       Date:  2013-01-13       Impact factor: 11.556

7.  Epithelial cell secretions from the human female reproductive tract inhibit sexually transmitted pathogens and Candida albicans but not Lactobacillus.

Authors:  C R Wira; M Ghosh; J M Smith; L Shen; R I Connor; P Sundstrom; G M Frechette; E T Hill; J V Fahey
Journal:  Mucosal Immunol       Date:  2010-11-03       Impact factor: 7.313

8.  C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.

Authors:  Qinxue Hu; Xin Huang; Robin J Shattock
Journal:  J Gen Virol       Date:  2010-09-01       Impact factor: 3.891

9.  Coreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected Ugandans.

Authors:  Edward Wright; Susan Mugaba; Paul Grant; Rosalind Parkes-Ratanshi; Lieve Van der Paal; Heiner Grosskurth; Pontiano Kaleebu
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

10.  Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones.

Authors:  Joshua Baalwa; Shuyi Wang; Nicholas F Parrish; Julie M Decker; Brandon F Keele; Gerald H Learn; Ling Yue; Eugene Ruzagira; Deogratius Ssemwanga; Anatoli Kamali; Pauli N Amornkul; Matt A Price; John C Kappes; Etienne Karita; Pontiano Kaleebu; Eduard Sanders; Jill Gilmour; Susan Allen; Eric Hunter; David C Montefiori; Barton F Haynes; Emmanuel Cormier; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2012-11-01       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.